Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Drops By 6.3%

HilleVax, Inc. (NASDAQ:HLVX) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,180,000 shares, a decline of 6.3% from the October 15th total of 1,260,000 shares. Currently, 6.4% of the company’s shares are short sold. Based on an average daily trading volume, of 259,400 shares, the short-interest ratio is currently 4.5 days.

HilleVax Trading Down 0.5 %

Shares of HLVX opened at $1.82 on Wednesday. The firm has a market cap of $90.65 million, a P/E ratio of -0.59 and a beta of 0.78. HilleVax has a 12-month low of $1.55 and a 12-month high of $20.22. The company’s 50-day moving average price is $1.83 and its 200 day moving average price is $5.60.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). Equities research analysts forecast that HilleVax will post -2.64 earnings per share for the current year.

Institutional Trading of HilleVax

A number of institutional investors and hedge funds have recently bought and sold shares of HLVX. Braidwell LP purchased a new stake in HilleVax during the third quarter worth about $1,873,000. Frazier Life Sciences Management L.P. increased its stake in HilleVax by 8.5% during the second quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock worth $153,523,000 after purchasing an additional 835,590 shares during the period. Point72 Asset Management L.P. purchased a new stake in HilleVax during the second quarter worth about $6,960,000. Trium Capital LLP purchased a new stake in HilleVax during the third quarter worth about $798,000. Finally, Affinity Asset Advisors LLC purchased a new stake in HilleVax during the second quarter worth about $3,844,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating and issued a $2.00 price objective on shares of HilleVax in a report on Monday, August 12th. Six analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.00.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.